acetazolamide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
56 59-66-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • acetazolamide
  • acetamox
  • acetazolamid
  • cidamex
  • nephramide
  • acetazolamide sodium
One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
  • Molecular weight: 222.24
  • Formula: C4H6N4O3S2
  • CLOGP: -0.98
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 115.04
  • ALOGS: -1.90
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.75 g O
0.75 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ
S (Water solubility) 0.64 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 90 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 75.14 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.37 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.65 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 13 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 27, 1953 FDA TEVA BRANDED PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Idiopathic intracranial hypertension 170.28 17.06 45 8197 2886 63477894
Angle closure glaucoma 152.80 17.06 39 8203 2180 63478600
Papilloedema 134.78 17.06 40 8202 3920 63476860
Hair follicle tumour benign 133.77 17.06 26 8216 405 63480375
Metabolic acidosis 132.80 17.06 79 8163 44990 63435790
Intraocular pressure increased 114.00 17.06 39 8203 6039 63474741
Choroidal effusion 101.49 17.06 21 8221 455 63480325
Intracranial pressure increased 88.21 17.06 31 8211 5196 63475584
Off label use 86.92 17.06 236 8006 674226 62806554
Choroidal detachment 72.15 17.06 14 8228 216 63480564
Complications of bone marrow transplant 56.74 17.06 13 8229 458 63480322
Hepatosplenic T-cell lymphoma 53.55 17.06 13 8229 590 63480190
Glaucoma 50.13 17.06 31 8211 18874 63461906
Retinal detachment 49.09 17.06 21 8221 5948 63474832
Macular detachment 43.09 17.06 8 8234 96 63480684
Acute generalised exanthematous pustulosis 42.19 17.06 23 8219 11076 63469704
Flat anterior chamber of eye 40.62 17.06 7 8235 53 63480727
Hypercapnia 37.83 17.06 17 8225 5414 63475366
Corneal oedema 37.71 17.06 12 8230 1481 63479299
Aggression 37.16 17.06 28 8214 23470 63457310
Photophobia 37.09 17.06 25 8217 17610 63463170
Intellectual disability 37.08 17.06 11 8231 1075 63479705
Drug ineffective 35.64 17.06 244 7998 1044521 62436259
Visual impairment 35.42 17.06 49 8193 84397 63396383
Hypotony of eye 33.94 17.06 7 8235 149 63480631
Sickle cell anaemia with crisis 33.15 17.06 16 8226 5987 63474793
Visual field defect 31.80 17.06 16 8226 6545 63474235
Ophthalmic vein thrombosis 31.36 17.06 7 8235 219 63480561
Lens dislocation 29.61 17.06 5 8237 33 63480747
Myopia 28.63 17.06 10 8232 1645 63479135
Haemorrhagic diathesis 28.16 17.06 13 8229 4402 63476378
Drug ineffective for unapproved indication 28.13 17.06 28 8214 34035 63446745
Persecutory delusion 26.92 17.06 11 8231 2779 63478001
Cerebral venous sinus thrombosis 26.91 17.06 10 8232 1962 63478818
Retinopathy haemorrhagic 26.79 17.06 4 8238 10 63480770
Dysphoria 26.71 17.06 13 8229 4953 63475827
Psychiatric decompensation 26.30 17.06 9 8233 1392 63479388
Product contamination microbial 26.14 17.06 6 8236 213 63480567
Myasthenic syndrome 25.12 17.06 6 8236 254 63480526
Joint space narrowing 24.66 17.06 7 8235 585 63480195
Iridocyclitis 24.53 17.06 10 8232 2512 63478268
Nephrocalcinosis 24.51 17.06 8 8234 1070 63479710
Retroperitoneal oedema 24.47 17.06 4 8238 21 63480759
Osteopenia 23.64 17.06 20 8222 19765 63461015
Toxic leukoencephalopathy 23.02 17.06 7 8235 744 63480036
CSF pressure increased 22.86 17.06 5 8237 142 63480638
Vision blurred 22.84 17.06 42 8200 91882 63388898
Transmission of an infectious agent via product 22.73 17.06 5 8237 146 63480634
Acute respiratory failure 22.50 17.06 25 8217 34460 63446320
Cross sensitivity reaction 22.50 17.06 9 8233 2153 63478627
Ocular surface disease 22.21 17.06 4 8238 40 63480740
Appetite disorder 21.97 17.06 13 8229 7308 63473472
Overlap syndrome 21.80 17.06 7 8235 889 63479891
Endophthalmitis 21.13 17.06 10 8232 3582 63477198
Arthritis infective 20.75 17.06 12 8230 6466 63474314
Diplopia 20.51 17.06 20 8222 23708 63457072
Cataract 19.40 17.06 30 8212 57023 63423757
Hyphaema 19.33 17.06 5 8237 294 63480486
Oral pain 19.24 17.06 21 8221 28373 63452407
Acidosis 19.13 17.06 14 8228 11219 63469561
Non-cardiogenic pulmonary oedema 18.98 17.06 6 8236 725 63480055
Ocular pemphigoid 18.94 17.06 4 8238 96 63480684
Vitreous disorder 18.82 17.06 4 8238 99 63480681
Lactic acidosis 18.78 17.06 24 8218 38263 63442517
Hyperventilation 18.72 17.06 11 8231 6105 63474675
Optic disc haemorrhage 18.52 17.06 4 8238 107 63480673
Conjunctival hyperaemia 18.35 17.06 8 8234 2371 63478409
Meningitis aseptic 18.34 17.06 10 8232 4813 63475967
Bacterial endophthalmitis 18.21 17.06 4 8238 116 63480664
Nasal flaring 17.87 17.06 3 8239 19 63480761
Optic neuritis 17.83 17.06 12 8230 8423 63472357
Hypersensitivity 17.59 17.06 8 8234 292677 63188103
Retinal vascular occlusion 17.57 17.06 5 8237 422 63480358
Product use in unapproved indication 17.44 17.06 57 8185 179023 63301757
Swelling 17.39 17.06 7 8235 275371 63205409
Foetal exposure during pregnancy 17.22 17.06 21 8221 31941 63448839
Skin warm 17.15 17.06 10 8232 5466 63475314
Rhinocerebral mucormycosis 17.15 17.06 5 8237 460 63480320

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraocular pressure increased 176.16 19.31 51 3872 5332 34947676
Metabolic acidosis 132.38 19.31 74 3849 43606 34909402
Choroidal detachment 131.85 19.31 25 3898 397 34952611
Angle closure glaucoma 95.26 19.31 22 3901 935 34952073
Toxic epidermal necrolysis 91.96 19.31 46 3877 21600 34931408
Choroidal effusion 83.16 19.31 15 3908 178 34952830
Drug ineffective 53.98 19.31 141 3782 456610 34496398
Congenital emphysema 48.58 19.31 6 3917 0 34953008
Intraocular pressure decreased 47.09 19.31 8 3915 65 34952943
Hyphaema 45.38 19.31 11 3912 576 34952432
Drug reaction with eosinophilia and systemic symptoms 45.19 19.31 34 3889 32978 34920030
Glaucoma 42.59 19.31 19 3904 6893 34946115
Visual acuity reduced 42.49 19.31 25 3898 16124 34936884
Corneal oedema 40.63 19.31 12 3911 1339 34951669
Ocular surface disease 39.63 19.31 7 3916 73 34952935
Off label use 36.30 19.31 116 3807 419408 34533600
Burkholderia test positive 30.38 19.31 9 3914 1014 34951994
Hypochloraemia 29.72 19.31 8 3915 637 34952371
Idiopathic intracranial hypertension 29.06 19.31 8 3915 693 34952315
Respiratory acidosis 28.31 19.31 13 3910 5037 34947971
Photocoagulation 27.99 19.31 4 3919 8 34953000
Acidosis hyperchloraemic 27.69 19.31 7 3916 436 34952572
Crystalluria 27.12 19.31 7 3916 474 34952534
Corneal opacity 25.75 19.31 7 3916 579 34952429
Product contamination microbial 24.92 19.31 7 3916 653 34952355
Trabeculectomy 24.90 19.31 4 3919 22 34952986
Visual impairment 22.96 19.31 24 3899 35778 34917230
Hypocapnia 22.72 19.31 5 3918 170 34952838
Transmission of an infectious agent via product 22.36 19.31 5 3918 183 34952825
Visual acuity tests abnormal 21.98 19.31 4 3919 50 34952958
Acute kidney injury 21.56 19.31 79 3844 304909 34648099
Bacterial endophthalmitis 21.06 19.31 4 3919 64 34952944
Hypercapnia 20.91 19.31 10 3913 4245 34948763
Dysmetria 20.89 19.31 6 3917 606 34952402
Endophthalmitis 19.57 19.31 9 3914 3499 34949509
Respiratory distress 19.54 19.31 22 3901 35643 34917365

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angle closure glaucoma 240.20 15.37 60 10840 2916 79730572
Intraocular pressure increased 212.79 15.37 70 10830 9135 79724353
Choroidal detachment 211.57 15.37 41 10859 595 79732893
Metabolic acidosis 177.93 15.37 121 10779 82408 79651080
Choroidal effusion 172.89 15.37 35 10865 642 79732846
Idiopathic intracranial hypertension 149.94 15.37 42 10858 3180 79730308
Hair follicle tumour benign 136.20 15.37 27 10873 443 79733045
Off label use 108.19 15.37 319 10581 906896 78826592
Papilloedema 99.68 15.37 36 10864 6197 79727291
Intracranial pressure increased 82.70 15.37 34 10866 8288 79725200
Drug ineffective 71.76 15.37 314 10586 1080599 78652889
Toxic epidermal necrolysis 70.01 15.37 54 10846 44527 79688961
Corneal oedema 68.97 15.37 22 10878 2598 79730890
Glaucoma 67.89 15.37 39 10861 19722 79713766
Hyphaema 61.95 15.37 16 10884 888 79732600
Ocular surface disease 60.34 15.37 11 10889 112 79733376
Hypercapnia 57.84 15.37 27 10873 8908 79724580
Complications of bone marrow transplant 51.99 15.37 13 10887 633 79732855
Retinal detachment 50.91 15.37 25 10875 9222 79724266
Transmission of an infectious agent via product 49.00 15.37 10 10890 191 79733297
Hepatosplenic T-cell lymphoma 48.03 15.37 13 10887 865 79732623
Product contamination microbial 47.07 15.37 13 10887 933 79732555
Visual impairment 44.81 15.37 59 10841 92072 79641416
Visual acuity reduced 44.75 15.37 35 10865 29434 79704054
Photophobia 43.92 15.37 30 10870 20498 79712990
Macular detachment 42.07 15.37 9 10891 218 79733270
Drug reaction with eosinophilia and systemic symptoms 40.69 15.37 47 10853 64197 79669291
Endophthalmitis 40.30 15.37 19 10881 6409 79727079
Flat anterior chamber of eye 39.14 15.37 8 10892 154 79733334
Bacterial endophthalmitis 38.30 15.37 8 10892 172 79733316
Ophthalmic vein thrombosis 36.01 15.37 8 10892 232 79733256
Visual field defect 34.16 15.37 19 10881 9026 79724462
Myopia 33.92 15.37 12 10888 1944 79731544
Vision blurred 32.97 15.37 55 10845 105843 79627645
Corneal opacity 32.87 15.37 10 10890 1010 79732478
Intraocular pressure decreased 32.51 15.37 7 10893 175 79733313
Acidosis hyperchloraemic 30.35 15.37 9 10891 833 79732655
Hypotony of eye 30.07 15.37 7 10893 251 79733237
Acute generalised exanthematous pustulosis 29.50 15.37 22 10878 17232 79716256
Non-cardiogenic pulmonary oedema 29.09 15.37 10 10890 1489 79731999
Acidosis 28.98 15.37 23 10877 19739 79713749
Retinal vascular occlusion 28.64 15.37 8 10892 599 79732889
Cerebral venous sinus thrombosis 28.47 15.37 11 10889 2280 79731208
Sickle cell anaemia with crisis 28.18 15.37 16 10884 7906 79725582
Hypocapnia 28.18 15.37 8 10892 635 79732853
Trabeculectomy 27.16 15.37 5 10895 54 79733434
Photocoagulation 26.58 15.37 4 10896 10 79733478
Iridocyclitis 26.50 15.37 12 10888 3692 79729796
Crystalluria 25.09 15.37 8 10892 943 79732545
Vitreous disorder 24.79 15.37 6 10894 255 79733233
Retroperitoneal oedema 24.27 15.37 4 10896 21 79733467
Osteopenia 24.03 15.37 20 10880 18344 79715144
Dysphoria 23.70 15.37 12 10888 4722 79728766
Joint space narrowing 23.27 15.37 7 10893 681 79732807
Respiratory acidosis 23.09 15.37 16 10884 11184 79722304
Eye pain 22.96 15.37 27 10873 37551 79695937
Intellectual disability 22.52 15.37 8 10892 1312 79732176
Lens dislocation 22.18 15.37 5 10895 155 79733333
Diplopia 22.05 15.37 25 10875 33441 79700047
Cataract 21.69 15.37 34 10866 62086 79671402
Multiple-drug resistance 21.56 15.37 14 10886 8794 79724694
Corneal disorder 21.54 15.37 9 10891 2282 79731206
Nephrocalcinosis 21.51 15.37 8 10892 1494 79731994
Somnolence 20.93 15.37 76 10824 238905 79494583
Haemorrhagic diathesis 20.87 15.37 12 10888 6072 79727416
Aggression 20.80 15.37 30 10870 50928 79682560
Punctate keratitis 20.79 15.37 7 10893 979 79732509
Appetite disorder 20.68 15.37 13 10887 7726 79725762
Overlap syndrome 20.53 15.37 7 10893 1017 79732471
Drug resistance 20.46 15.37 27 10873 42186 79691302
Burkholderia test positive 19.99 15.37 6 10894 579 79732909
CSF pressure increased 19.79 15.37 5 10895 254 79733234
Retinopathy haemorrhagic 19.72 15.37 4 10896 74 79733414
Meningitis aseptic 19.43 15.37 12 10888 6916 79726572
Conjunctival hyperaemia 18.69 15.37 10 10890 4403 79729085
Prostaglandin analogue periorbitopathy 18.67 15.37 3 10897 13 79733475
Acute respiratory failure 18.62 15.37 31 10869 59510 79673978
Blindness 18.36 15.37 21 10879 28362 79705126
Product use in unapproved indication 18.15 15.37 75 10825 250284 79483204
Hyperventilation 17.98 15.37 12 10888 7887 79725601
Visual acuity tests abnormal 17.94 15.37 4 10896 118 79733370
Myasthenic syndrome 17.84 15.37 6 10894 836 79732652
Intraventricular haemorrhage 17.73 15.37 10 10890 4877 79728611
Persecutory delusion 17.69 15.37 10 10890 4899 79728589
Brain stem haematoma 17.65 15.37 4 10896 127 79733361
Arthritis infective 17.48 15.37 12 10888 8259 79725229
Optic disc haemorrhage 17.39 15.37 4 10896 136 79733352
Vitreous haemorrhage 17.39 15.37 9 10891 3704 79729784
Neutropenia 17.10 15.37 9 10891 287701 79445787
Retinopathy 16.99 15.37 9 10891 3882 79729606
Psychiatric decompensation 16.84 15.37 9 10891 3954 79729534
Anterior chamber disorder 16.81 15.37 4 10896 158 79733330
Presyncope 16.51 15.37 24 10876 41030 79692458
Drug ineffective for unapproved indication 16.46 15.37 27 10873 51211 79682277
Dysmetria 16.43 15.37 6 10894 1065 79732423
Respiratory alkalosis 16.13 15.37 9 10891 4302 79729186
Iris adhesions 16.10 15.37 5 10895 541 79732947
Blepharitis 15.87 15.37 8 10892 3116 79730372
Drug clearance decreased 15.40 15.37 8 10892 3319 79730169

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01EC01 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Carbonic anhydrase inhibitors
FDA CS M0020790 Sulfonamides
FDA MoA N0000000235 Carbonic Anhydrase Inhibitors
FDA EPC N0000175517 Carbonic Anhydrase Inhibitor
MeSH PA D000927 Anticonvulsants
MeSH PA D002257 Carbonic Anhydrase Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004232 Diuretics
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D045283 Natriuretic Agents
CHEBI has role CHEBI:23018 EC 4.2.1.1 inhibitor
CHEBI has role CHEBI:35498 diuretics
CHEBI has role CHEBI:35623 anticonvulsants

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Malignant glaucoma indication 10100008
Anoxia due to high altitude indication 42883007
Absence seizure indication 79631006
Open-angle glaucoma indication 84494001 DOID:1067
Secondary glaucoma indication 95717004
Edema indication 267038008
Peripheral edema indication 271809000
Angle-closure glaucoma indication 392291006 DOID:13550
Peripheral Edema due to Chronic Heart Failure indication
Metabolic alkalosis off-label use 1388004
Myoclonic seizure off-label use 37356005
Idiopathic intracranial hypertension off-label use 68267002 DOID:11459
Benign intracranial hypertension off-label use 68267002 DOID:11459
Familial hypokalemic periodic paralysis off-label use 82732003 DOID:14452
Epilepsy off-label use 84757009 DOID:1826
Obstructive hydrocephalus off-label use 230746009 DOID:14159
Familial periodic paralysis off-label use 267607008 DOID:1029
Tonic-clonic epilepsy off-label use 352818000 DOID:7725
Simple partial seizure off-label use 117891000119100
Urine Alkalinization off-label use
Hydrocephalus due to Intraventricular Hemorrhage off-label use
Mixed Epilepsy off-label use
Renal tubular acidosis contraindication 1776003 DOID:14219
Respiratory acidosis contraindication 12326000
Hyperkalemia contraindication 14140009
Metabolic acidosis, normal anion gap, acidifying salts contraindication 18104000
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Decreased respiratory function contraindication 80954004
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Disease of liver contraindication 235856003 DOID:409
Disorder of electrolytes contraindication 237840007
Primary adrenocortical insufficiency contraindication 373662000
Recurrent Calcium Renal Calculi contraindication




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Mild congestive heart failure Indication
Dogs Rapid reduction of intraocular pressure Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Vetamox Soluble Powder Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.04 acidic
pKa2 9.21 acidic
pKa3 1.84 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Carbonic anhydrase 12 Enzyme INHIBITOR Ki 8.60 CHEMBL CHEMBL
Carbonic anhydrase 1 Enzyme INHIBITOR Ki 7.92 CHEMBL CHEMBL
Carbonic anhydrase 4 Enzyme INHIBITOR Ki 7.96 CHEMBL CHEMBL
Carbonic anhydrase 2 Enzyme INHIBITOR Ki 8.48 CHEMBL CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 7.22 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 7.27 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 8.60 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 8.51 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 7.96 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 7.39 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 8.24 CHEMBL
Carbonic anhydrase Enzyme Ki 9.10 CHEMBL
Carbonic anhydrase V Enzyme Ki 8.74 CHEMBL
Carbonic anhydrase-related protein 11 Enzyme Ki 8.24 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 8.05 CHEMBL
Aquaporin-1 Transporter WOMBAT-PK
Carbonic anhydrase Enzyme Ki 7.70 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 7.77 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 7.15 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 7.80 CHEMBL
Carbonic anhydrase Enzyme Ki 7.22 CHEMBL
Carbonic anhydrase Enzyme Ki 4.92 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.14 CHEMBL
Carbonic anhydrase Enzyme Ki 7.09 CHEMBL
Carbonic anhydrase Enzyme Ki 7.40 CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme Ki 7.92 CHEMBL
Carbonic anhydrase Enzyme Ki 7.96 CHEMBL
Alpha carbonic anhydrase Enzyme Ki 7.80 CHEMBL
Endochitinase Enzyme Ki 4.68 CHEMBL
Carbonic anhydrase Enzyme Ki 7.13 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 8 CHEMBL
Carbonic anhydrase Enzyme Ki 5.24 CHEMBL
Astrosclerin-3 Enzyme Ki 7.29 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 6.60 CHEMBL
Delta carbonic anhydrase Unclassified Ki 7.08 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 8.05 CHEMBL
Carbonic anhydrase 2 Enzyme IC50 6.02 CHEMBL
Carbonic anhydrase Enzyme IC50 7.80 CHEMBL
Carbonic anhydrase Enzyme Ki 7.57 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 4.08 CHEMBL
Carbonic anhydrase Enzyme Ki 7.56 CHEMBL
Carbonic anhydrase Enzyme Ki 7.12 CHEMBL
Carbonic anhydrase, alpha family Unclassified Ki 8.37 CHEMBL
Carbonate dehydratase Enzyme Ki 8.35 CHEMBL
Carbonic anhydrase 2, isoform A; LD26647p Enzyme Ki 7.11 CHEMBL
Carbonic anhydrase 1; GH09688p Enzyme Ki 6.97 CHEMBL

External reference:

IDSource
4017898 VUID
N0000146250 NUI
D00218 KEGG_DRUG
1424-27-7 SECONDARY_CAS_RN
167 RXNORM
C0000981 UMLSCUI
CHEBI:27690 CHEBI
AZM PDB_CHEM_ID
CHEMBL20 ChEMBL_ID
DB00819 DRUGBANK_ID
CHEMBL1200814 ChEMBL_ID
D000086 MESH_DESCRIPTOR_UI
1986 PUBCHEM_CID
6792 IUPHAR_LIGAND_ID
481 INN_ID
O3FX965V0I UNII
33664007 SNOMEDCT_US
372709008 SNOMEDCT_US
72469007 SNOMEDCT_US
4017898 VANDF
4017899 VANDF
2596 MMSL
4121 MMSL
814 MMSL
d00161 MMSL
002286 NDDF
002287 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9006 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 20 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9503 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 20 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9503 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 20 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9503 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 20 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0527-1050 TABLET 250 mg ORAL ANDA 19 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6663 TABLET 250 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6663 TABLET 250 mg ORAL ANDA 18 sections
AcetaZOLAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-567 TABLET 250 mg ORAL ANDA 18 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 10135-772 TABLET 125 mg ORAL ANDA 19 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 10135-773 TABLET 250 mg ORAL ANDA 19 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 16729-331 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 21 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 16729-331 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 21 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-120 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 11 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-287 TABLET 125 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-287 TABLET 125 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-287 TABLET 125 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-287 TABLET 125 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-288 TABLET 250 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-288 TABLET 250 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-288 TABLET 250 mg ORAL ANDA 18 sections
acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-288 TABLET 250 mg ORAL ANDA 18 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-313 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 16 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-313 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 16 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-787 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 12 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-787 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 12 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-787 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 12 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-831 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 16 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 23155-831 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 16 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 29033-030 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 22 sections
Acetazolamide HUMAN PRESCRIPTION DRUG LABEL 1 29033-030 CAPSULE, EXTENDED RELEASE 500 mg ORAL ANDA 22 sections